Pan-Canadian review of cancer drugs will not be binding on provinces

Vogel, Lauren
June 2010
CMAJ: Canadian Medical Association Journal;6/15/2010, Vol. 182 Issue 9, p887
Academic Journal
The article reports on the pan-Canadian Oncology Drug Review (pDOCR) of cancer drugs in Canada. It states that the review process will be launched in 2010 in all provinces of Canada to provide common recommendations on clinical and cost-effectiveness of cancer drugs. It says that the clinical, pharmacoeconomic, and guideline evidence for oncology drug submissions and recommendations will be evaluated by an expert committee. It adds that the review is expected to be completed within five months.


Related Articles

  • Cost versus benefit in non-surgical management of patients with cancer. Timothy, Adrian R.; Brewin, Thurstan; Chamberlain, Jocelyn; Horwich, A.; Jennett, Bryan; Kind, Paul; Maxwell, Robert; Raftery, James; Rees, Gareth; Selby, Peter; Skranabek, Petr; Slevin, M.L.; Smith, A.J.; Stoll, Basil; Sutcliffe, Simon; Till, James; Whitehouse, J.M.A. // BMJ: British Medical Journal (International Edition);8/13/88, Vol. 297 Issue 6646, p471 

    Investigates the need for medical audit of the treatment of patients with cancer. Comparison between the cost of curative and palliative treatment; Basis of optimum management for individual patients; Importance of considering social and financial consequences of actions of cancer physicians.

  • Cost-effectiveness helps sort prevention priorities. Reynolds, Tom // JNCI: Journal of the National Cancer Institute;6/15/94, Vol. 86 Issue 12, p888 

    Discusses the role of cost-effectiveness research in cancer therapy. Promotion of the benefits of prevention; Practice of cancer screening and other interventions on large populations; Comparison of the cost-effectiveness and the perceived urgency of screening for cervical cancer; Primary...

  • Meeting highlights.  // Formulary;Jun97, Vol. 32 Issue 6, p638 

    Presents Disease Management Congress' data-collection strategies on issues on cancer treatment. Ways of collecting and presenting data; Documenting a problem area through use of patient survey; Quality of collected data; Trends in the economics of cancer drug treatment and its effect on...

  • Prospective audit on the care of breast cancer patients in Dumfries and Galloway. Walls, A. // Journal of the Royal College of Surgeons of Edinburgh;Dec99, Vol. 44 Issue 6, p402 

    Presents an abstract of the study 'Prospective audit on the care of breast cancer patients in Dumfries and Galloway,' by A. Walls, presented at the Symposium of Audit on Surgical Practice, March 3, 1999. Study setting in Scotland.

  • Breast cancer indication for bevacizumab.  // OB/GYN Clinical Alert;Sep2010 Pharmacology, p2 

    The article reports on the recommendation of the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to remove the indication for breast cancer treatment in bevacizumab.

  • Erlotinib marginally cost-effective.  // British Journal of Hospital Medicine (17508460);Mar2010, Vol. 71 Issue 3, p129 

    The article reports on the cost-effectiveness of erlotinib for the treatment of patients with advanced non-small cell lung cancer.

  • A decade of new cancer drugs: good value for money.  // PharmacoEconomics & Outcomes News;6/15/2013, Issue 680, p10 

    The article discusses research being done on the cost effectiveness of newly approved cancer therapies, which references a study by A. Winn et al presented at the 2013 International Society for Pharmacoeconomics and Outcomes Research meeting.

  • Is NAB-P + GEM cost effective in the UK?  // PharmacoEconomics & Outcomes News;Apr2015, Vol. 725 Issue 1, p18 

    The article discusses the cost effectiveness of the pancreatic cancer treatment nab-paclitaxel (NAB-P) plus gemcitabine (GEM) due to higher survival rate of patients.

  • Current treatments for prostate cancer not cost effective.  // PharmacoEconomics & Outcomes News;05/11/2013, Issue 678, p4 

    The article reports that existing treatment strategy for metastatic castration-resistant prostrate cancer in the U.S. in 2013 is not cost-effective, which was concluded after an analysis of costs and progression-free survival associated with various treatment options in the country.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics